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Abstract. The recombinant plasmid pBHIV-1 carrying the 
long terminal repeat (LTR) of the human immunodeficiency 
virus 1 (HIV-1), linked to the reporter chlorampenicol acetyl 
transferase (CAT) gene, was introduced into human and rat 
fibroblasts. Stable transfectants were obtained which were 
resistant to geneticin and expressed CAT-activity from the 
HTV-1 LTR. The response to TNFa was studied. It was found 
that, at the optimum concentration of 100 IU/ml in human and 
1000 IU/ml in rat fibroblasts, the expression of CAT was 
stimulated by 2.1 and 2.5-fold respectively. Our findings 
suggest that TNF-a in physiological concentrations can trans­
criptionally activate the HTV-1 LTR sequences and this may 
play an important role in the pathogenesis of HIV infection. 
TNF-a is a polypeptide cytokine which is produced by 
activated monocytes or macrophages and was originally de­
scribed as a mediator of hemorrhagic necrosis of certain 
murine tumors (1,2,3). TNF-a alters the levels of various 
surface components of the blood vessel wall, such as blood 
coagulation enzyme receptors, leukocyte-adhesive receptors 
and class I major histocompatibility complex antigens, which 
may have relevance to its effects in septic shock, angiogenesis 
and tumor growth (4). The action of TNF-a peptide hormone 
occurs through membrane receptors and leads to the trans­
cription of specific genes within relevant target cells (5). The 
mechanism of transduction of these signals which alter gene 
expression is largelly unknown, but probably involves a 
sequence of enzymatic steps that activate factors in the 
nucleus that modulate transcription (5). 
The human immunodeficiency virus (HIV) is the etiologic 
agent of the acquired immune deficiency syndrome (AIDS) 
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(6,7,8). The LTR of HIV shows a complex organization with 
several sites recognized to be eis and frans-acting control 
elements through which cellular factors can regulate gene 
expression (9,10). In a previous study, it has been shown that 
activation of infected T-cells increases the pool of the active 
transcription factor known as NF-κΒ. This factor binds to a 
11 base pair motif that is repeated twice in the enhancer 
region of the HIV-1 LTR known as the NF-κΒ site (11, 12). 
TNF-a (5), phorbol esters (13), mitogenic lectins (12) and 
interleukin 1 (5) have all been shown to increase the produc­
tion of HIV-1 by acting through NF-κΒ in T-cells. 
In the present study we have examined the response to 
TNF-a from the HIV-1 LTR in two different model systems, 
those of human and rat fibroblasts. Our findings suggest that 
TNF- α at low concentrations can provide potent inductive 
signals for the expression of HIV in chronically infected cells 
and has important implications for understanding the 
pathogenic mechanism of HIV infection in humans. 
Materials and Methods 
Recombinant plasmids and cell lines. Plasmid pBHIVl carrying a 728 bp 
(Xhol)-Hind III DNA fragment containing the HIV-1 LTR sequences 
was constructed by inserting a 1.9 kb BamHI fragment carrying the 
aminoglycoside phosphotransferase aph gene as a selectable marker for 
geneticin into the single Bam HI site of plasmid pBC12/HIV/CAT (14). 
Plasmid pBC12/HIV/CAT was obtained from B.R. Cullen (14). 
The spontaneously immortalized rat 208F and the SV40 immortalized 
human MRCSV40TGR fibroblasts were used as recipients to obtain the 
RFBHIV1-1 and SVTGHIV1-1 stable geneticin resistant transfectant cell 
lines with plasmid pBHIVl DNA (Figure 1). Transfections were carried 
out using the calcium phophate technique (16) as modified (17). 
Treatment of cells and CAT assays. Cells were plated at 1.5xl06/75cm2 
flask in Ham's F12 medium containing (10%) FCS at (37°C). 48 hours 
later the medium was replaced with Ham's F12 medium containing 10% 
FCS and the various concentrations of TNF (Amersham). 1 IU of TNF-a 
corresponding to 10"4 μg of protein is designated as the amount of TNF-a 
that is required to mediate half-maximal cytotoxicity with L929 and/or 
WEHI 164 cells in the presence of Actinomycin D (18). Cells were 
harvested 24h later and tested for CAT activity as previously described 
(19). 
In brief, the protein content was estimated using the Biorad Protein 
Assay. 100 μg of protein extract were mixed with 10 μΙ of 4M Acetyl CoA 
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Figure 1. Structure of pBHIVI plasmid used to transfeci the rat 208F and 
human MRCSV40TGR cells. The 1.9 kb Bam HI fragment carrying the 
aph gene under the HSV-1 thymidine kinase promoter and 3-polyadenyla-
tion signal was derived from plasmid p26 (obtained from Jas Lang, 
Beatson Institute for Cancer Research) and was inserted into the single 
Bam HI site of plasmid pBC12IHlVICAT. Thin line, plasmid sequences; 
thick box, aph containing insert; open box, HIV L TR sequences; hatched 
box, cat gene; H, HindlII; B, Bam HI. Arrows indicate transcriptional 
orientation. Maps are not drawn to scale. 
element (9). In a previous study we have investigated the 
effect of growth factors, i.e. insulin and EGF, and hormones, 
i.e. Hydrocortizone and Dexamethasone, on the transcrip­
tion activity of HIV LTR (10). In the present study we have 
found that TNF-ct at the optimum concentrations stimulated 
the expression of the reporter CAT gene from the HIV LTR 
in human and rat fibroblasts by 2.1 and 2.6-fold respectively. 
Although the action of TNF-a in HIV activation is not 
clear, several lines of evidence suggest that this cytokine may 
play a role in the mechanism of viral infection (13). Given 
also the fact that HIV-infected individuals are frequently 
infected with a variety of microbes that can lead to the 
secretion of TNFs by macrophages and T-cells, understand­
ing the mode of action of TNF-a in expression of HIV is of 
great importance. This cytokine believed to act on HIV LTR 
through the NF-κΒ induction. Several reports support the 
finding that TNF-a induces expression of NF-κΒ (5, 12, 13). 
TNF-a induces expression of NF-xB-specific DNA - binding 
proteins, leading to enhancement of transcrition from LTR in 
infected T-cell clones. Our findings are consistent with the 
proposed mechanism, as we have observed a significant 
increase in HIV LTR expression in transfectants treated with 
TNF-a. Furthermore we showed that TNF-a may exert the 
above effect in fibroblasts of human and rat origin. 
(Sigma) and 2 μΐ of 14C-Chloramphenicol (57 mCi/mmol) (Amcrsham) 
were added. The mixture was incubated at 37°C for 90 min and 0.6 ml of 
ethyl acetate was then used to extract the chloramphenicol. The organic 
layer was dried and taken up in 30 μΐ of ethyl acetate, spotted on silica gel 
thin-layer plates and run with chloroform-methanol (95:5). After auto­
radiography, spots were cut out and counted. 
Results 
TNF-a enhances transcription from the HIV LTR sequences. 
The recipient rat 208F and human MRCSV40TGR and their 
derivative RFBHIV1-1 and SVTGHIV1-1 transfectant cell 
lines respectively were treated with TNF-a at concentrations 
between 10-5xl03 IU/ml. A representative CAT-assay is 
shown in Figure 2(a) and the corresponding histogram in 
Figure 2 (b). Optimal stimulation was obtained at 100 IU/ml 
in SVTGHIV1-1 and 1000 IU/ml in RFBHIV1-1 cells. CAT 
activity increases 2.1 and 2.5-fold respectively. 
The transfectant SVTGHIV1-1 cells were treated with 
TNF-a (100 IU/ml) at various time intervals. A representa­
tive CAT assay is shown in Figure 3 (a, b). Optimal stimula­
tion was obtained within 24 hours, where CAT activity 
increased 2.6-fold. 
Discussion 
The human immunodeficiency virus LTR contains several 
defined regulatory elements (9). Among them are a trans­
acting responsive element (20), an enhancer region including 
binding sites for NF-κΒ and Spi transcription factors, a 
phorbol ester inducible element and a negative regulatory 
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Figure 2. ö. Chromatogram of representative CAT assays with extracts from recipients' and transfectants' RFBHIVl-l and SVTGHIVl-l cells 
respectively, with and without treatment with TNF-a. 
b. Induction of CAT activity by TNF-a, RFBHIVl-l or SVTGHIVl-l cells were plated at 1.5xl(/'/75cm2 flask in Ham's F12 medium containing 10% 
FCS at 3TC. 48 hours later the medium was replaced with Ham's F12 containing 10% FCS and the various concentrations of TNF-a. Cells were 
harvested 24 hours later and tested for CAT activity as described in Materials and Methods. Relative values of CAT activity in RFBHIVl-l and 
SVTGHIVI-1 cells were 1.2 and 35 nmole acetylated chloramphenicol/ßg protein per hour of incubation respectively. The average from three experiments 
is given. Standard deviation was less than 3% of the average values. 
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Figure 3. Induction of CAT activity in SVTGHIV1-1 cells by TNF-a at various times post-treatment. 
a. Chromatogram for representative CAT assays with extracts from SVTGHIV1-1 celh treated with 100 W/ml TNF-a at various times. 
b. CAT values were computed and are presented in histograms as described in Figure 2b. 
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